Characterization of Humoral and Cellular Immune Responses Elicited by Influenza Vaccination in Healthy Adults

Conditions

• Influenza, Human

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Accepted

Interventions

• Seasonal influenza vaccine — BIOLOGICAL
  The seasonal influenza vaccine is administered intramuscularly at a dose of 15 ug of HA per component, as approved by the FDA.

Study Details

Cellular and humoral immune responses before and after seasonal influenza vaccination will be assessed. Each year, up to 100 participants will be enrolled. To study age-specific differences in immune responses, participants with various years of birth will be enrolled. The investigators hypothesize that humans with different birth years will mount antibody and cellular responses of different specificities following seasonal influenza vaccination.

Key Dates

Start date

Oct 7, 2021

Status verified

Feb 2026

Primary completion

Apr 1, 2027

Completion

Mar 31, 2028

Study Design

Enrollment

700 participants (estimated)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

BASIC_SCIENCE

Arms

• Experimental: Influenza vaccination
  Adults will receive a seasonal, inactivated, quadrivalent influenza vaccine administered intramuscularly at a dose of 15 ug of HA per component, as approved by the FDA.

Primary Outcome Measure

Effect of year of birth on neutralizing antibody titers elicited by influenza vaccination [ Time Frame: 7 years ]

Central Contacts

• Scott Hensley, PhD
  215-573-3756
  [email protected]
• Elizabeth Drapeau, PhD
  215-573-3756
  [email protected]

Locations (1)

Find similar trials in Philadelphia, PA